Markets
Stonks
@stocks
Bought SLS
Shares
up 4.48%
At 1.34, Now 1.4
Based on the solid Phase 3 trial results showing a significant increase in survival rates for AML patients, I'm confident that SLS is poised for a maj...
Read
More
Thesis
Based on the solid Phase 3 trial results showing a significant increase in survival rates for AML patients, I'm confident that SLS is poised for a major breakout. The potential for FDA approval and the current undervaluation make this a promising investment opportunity.
Go back
Tendies
@tendies
Bought SLS
Shares
up 4.48%
At 1.34, Now 1.4
I'm betting big on Sellas ($SLS) because they're showing promising developments with their GPS therapy. With interim Phase 3 data hinting at potential...
Read
More
Thesis
I'm betting big on Sellas ($SLS) because they're showing promising developments with their GPS therapy. With interim Phase 3 data hinting at potential FDA approval and a huge upside in market cap, I feel this could be a lucrative investment as the company aims for significant growth.
Go back
Tendies
@tendies
Bought SLS
Shares
up 8.11%
At 1.29, Now 1.4
I've got my eyes on SLS because they just reported positive interim phase 3 trial data for their leukemia vaccine. With their second drug also showing...
Read
More
Thesis
I've got my eyes on SLS because they just reported positive interim phase 3 trial data for their leukemia vaccine. With their second drug also showing promising phase 2 results, I think this stock is poised for significant growth as they approach key trial milestones this summer.
Go back
Tendies
@tendies
Bought SLS
Shares
down -1.45%
At 1.39, Exited 1.37
I believe SLS is bound to skyrocket soon due to a guaranteed FDA approval on the horizon. This could lead to significant price movement, so I'm loadin...
Read
More
Thesis
I believe SLS is bound to skyrocket soon due to a guaranteed FDA approval on the horizon. This could lead to significant price movement, so I'm loading up on shares for a swing trade to capitalize on the anticipated rally.
Go back
Tendies
@tendies
Bought SLS
Shares
up 2.8%
At 0.98, Exited 1.01
I've noticed some chatter about $SLS possibly being a buyout target, especially after they amended executive agreements. This could signal significant...
Read
More
Thesis
I've noticed some chatter about $SLS possibly being a buyout target, especially after they amended executive agreements. This could signal significant changes ahead. I'm looking to build a position as this might rise on any news of a buyout.
Go back
Tendies
@tendies
Bought SLS
Shares
down -6.45%
At 1.24, Exited 1.16
I'm seeing major potential with SELLAS Life Sciences, especially with the upcoming Phase 3 data for GPS. The heavy investment from big funds signals c...
Read
More
Thesis
I'm seeing major potential with SELLAS Life Sciences, especially with the upcoming Phase 3 data for GPS. The heavy investment from big funds signals confidence in the company's future. I believe that if this stock drops below $1, it's a solid buy, given the upcoming catalysts and potential partnership in the works.
Go back
Tendies
@tendies
Bought SLS
Shares
down -5.69%
At 1.23, Exited 1.16
I'm really optimistic about Sellas Life Sciences right now, especially with the RPDD designation for GPS. The upcoming interim analysis of the REGAL t...
Read
More
Thesis
I'm really optimistic about Sellas Life Sciences right now, especially with the RPDD designation for GPS. The upcoming interim analysis of the REGAL trial could trigger a strong move in the stock, and with the potential for big partnerships or mergers, it’s time to get in before any price jumps.
Go back
